thalidomide has been researched along with Skin Neoplasms in 49 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)." | 9.24 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017) |
| "The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to proceed with additional trials of this combination." | 9.14 | Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 9.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "This phase 1 study evaluated the safety and tolerability of adjuvant treatment with subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF) administered in combination with escalating doses of thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high risk for recurrence." | 9.14 | A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. ( Gillett, M; Lutzky, J; Nunez, Y; Spitler, L; Weber, R, 2009) |
| " The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma." | 9.14 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 9.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| "There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases." | 9.13 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008) |
| "Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma." | 9.12 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007) |
| "The combination of temozolomide and thalidomide is well tolerated in patients with very advanced heavily pretreated metastatic melanoma." | 9.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 9.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years)." | 9.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 9.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 9.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 7.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 7.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma." | 6.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| "Thalidomide was given orally at a daily dose of 200 mg/day, which was then escalated every 2 weeks by 200 mg/day as tolerated to a maximum of 800 mg/day." | 6.71 | Phase II study of thalidomide in patients with metastatic malignant melanoma. ( Cancela, AI; Costa, TD; Di Leone, LP; Fernandes, S; Reiriz, AB; Richter, MF; Schwartsmann, G, 2004) |
| " In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment." | 6.71 | Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. ( Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J, 2004) |
| "Treatment with thalidomide stopped the progression of the disease in two cases." | 5.91 | Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report. ( Abdollahimajd, F; Diab, R; Kaddah, A; Rakhshan, A; Shahidi Dadras, M, 2023) |
| "EORTC 21081 was a randomized phase III study of observation alone versus lenalidomide maintenance (25 mg po for 21 days) after debulking therapy in patients with advanced-stage cutaneous T-cell lymphomas (CTCLs)." | 5.24 | A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs. ( Bagot, M; Beylot-Barry, M; Chaby, G; Cowan, R; Dalle, S; Fox, CP; Hasan, B; Jonak, C; Knobler, R; Marreaud, S; Morris, S; Quaglino, P; Ritchie, D; Romero, PLO; Scarisbrick, J; Servitje, O; Shah, E; Stadler, R; Väkevä, L; Vermeer, MH; Whittaker, S, 2017) |
| "This phase 1 study evaluated the safety and tolerability of adjuvant treatment with subcutaneous granulocyte macrophage colony-stimulating factor (GM-CSF) administered in combination with escalating doses of thalidomide in patients with surgically resected stage II (T4), III, or IV melanoma at high risk for recurrence." | 5.14 | A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. ( Gillett, M; Lutzky, J; Nunez, Y; Spitler, L; Weber, R, 2009) |
| "The addition of thalidomide to dacarbazine in metastatic melanoma yielded activity insufficient to proceed with additional trials of this combination." | 5.14 | Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma. ( Chang, JL; Farrell, K; Jones, A; Muggia, F; Oratz, R; Ott, PA; Pavlick, AC, 2009) |
| "In limited institution phase 2 studies, thalidomide and temozolomide has yielded response rates (RRs) up to 32% for advanced melanoma, leading to the use of this combination as "standard" by some." | 5.14 | Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508. ( Clark, JI; Da Silva, DM; Flaherty, LE; Hutchins, LF; Kast, WM; Liu, PY; Moon, J; Sondak, VK; Sosman, JA; Thompson, JA, 2010) |
| "The results of an international, multicenter, randomized, double-blind, controlled study assessing the efficacy and safety of lenalidomide treatment in patients with refractory stage IV metastatic malignant melanoma are reported." | 5.14 | Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. ( Eisen, T; Glaspy, J; Hamilton, A; Hersey, P; Jungnelius, JU; Knight, RD; Millward, M; Trefzer, U, 2010) |
| " The higher dose of lenalidomide did not improve response rate, time to progression, or OS of patients with relapsed/refractory stage IV melanoma." | 5.14 | Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. ( Agarwala, SS; Atkins, MB; Bedikian, AY; Glaspy, J; Jungnelius, JU; Knight, RD; O'Day, S; Richards, JM, 2009) |
| "There were no objective responses in the brain but single agent Thalidomide has some activity in melanoma patients with brain metastases." | 5.13 | A phase II study of thalidomide in patients with brain metastases from malignant melanoma. ( Bastholt, L; Larsen, S; Lindeløv, B; Vestermark, LW, 2008) |
| "The combination of temozolomide and thalidomide is well tolerated in patients with very advanced heavily pretreated metastatic melanoma." | 5.12 | A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma. ( Arce-Lara, C; Kloecker, GH; Laber, DA; McMasters, KM; Miller, DM; Okeke, RI; Schonard, CL; Taft, BS, 2006) |
| "Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma." | 5.12 | Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. ( Clark, JI; Flaherty, LE; Hutchins, LF; Lange, MK; Moon, J; Sondak, VK; Thompson, JA, 2007) |
| "Preliminary studies suggesting that extended-dose temozolomide with thalidomide is safe and active in patients with metastatic melanoma have led to frequent use of this oral regimen." | 5.12 | Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). ( Haluska, FG; Hodgson, L; Houghton, AN; Hwu, WJ; Krown, SE; Niedzwiecki, D, 2006) |
| "The aim of this study was to determine the antitumour activity and toxicity of thalidomide in patients with metastatic melanoma." | 5.11 | Phase II study of thalidomide in patients with metastatic melanoma. ( Legha, SS; Pawlak, WZ, 2004) |
| "Patients with histologically confirmed metastatic melanoma and measurable brain metastases received temozolomide (75 mg/m2 per day for 6 weeks with a 2-week break between cycles) plus concomitant thalidomide (200 mg/day escalating to 400 mg/day for patients < 70 years or 100 mg/day escalating to 250 mg/day for patients > or = 70 years)." | 5.11 | Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. ( Chapman, PB; Houghton, AN; Hwu, WJ; Krown, SE; Lamb, LA; Lis, E; Livingston, PO; Menell, JH; Merrell, J; Panageas, KS; Williams, LJ; Wolchok, JD, 2005) |
| "One hundred eighty-one patients with metastatic melanoma were randomly assigned to receive up to six 4-weekly cycles consisting of temozolomide 200 mg/m2 every 8 hours for five doses, or temozolomide 200 mg/m2 daily for days 1 to 5 plus interferon alfa-2b 5 MU (million International Units) subcutaneously three times a week, or temozolomide 150 mg/m2 (increased after one cycle to 200 mg/m2) daily on days 1 to 5 plus thalidomide 100 mg daily days 1 to 28." | 5.10 | Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. ( Arance, A; Ashcroft, L; Clamp, A; Danson, S; Hodgetts, J; Lomax, L; Lorigan, P; Middleton, MR; Ranson, M; Thatcher, N, 2003) |
| " Subsequent investigations resulted in the diagnosis of type I cryoglobulinemia; the lesions resolved completely following treatment of the underlying disorder with lenalidomide." | 3.79 | Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner. ( Boyapati, A; Khan, S; Mar, A; Sheridan, A, 2013) |
| "In this report, we describe two new venous thrombosis cases occurring during a treatment with thalidomide." | 3.71 | [Thrombotic accidents induced by thalidomide: two cases]. ( Gachon, J; Grob, JJ; Richard, MA, 2002) |
| "We report two patients who were treated with thalidomide for resistant multiple myeloma (MM) and developed extramedullary plasmacytomas despite a good response in the bone marrow." | 3.71 | Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma. ( Avigdor, A; Ben-Bassat, I; Hardan, I; Levi, I; Raanani, P, 2001) |
| " Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy." | 3.69 | Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. ( Bonaccorsi, P; Calvieri, S; Carlesimo, M; Giustini, S; Rossi, A, 1995) |
| "Thalidomide+IFN is a safe and tolerable palliative treatment for previously treated stage IV melanoma." | 2.73 | A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment. ( Berd, D; Mastrangelo, MJ; Sato, T; Solti, M, 2007) |
| " In all, 87% of adverse effects were classified as grade 1 or grade 2 according to Common Toxicity Criteria and there were no serious adverse events attributable to CC-5013 treatment." | 2.71 | Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. ( Bartlett, JB; Clarke, IA; Dalgleish, AG; Dredge, K; Kristeleit, H; Michael, A; Muller, GW; Nicholson, S; Pandha, H; Polychronis, A; Stirling, DI; Zeldis, J, 2004) |
| "Thalidomide was given orally at a daily dose of 200 mg/day, which was then escalated every 2 weeks by 200 mg/day as tolerated to a maximum of 800 mg/day." | 2.71 | Phase II study of thalidomide in patients with metastatic malignant melanoma. ( Cancela, AI; Costa, TD; Di Leone, LP; Fernandes, S; Reiriz, AB; Richter, MF; Schwartsmann, G, 2004) |
| "Hemangiomas are benign neoplasms of the vasculature frequently encountered in children." | 2.47 | Hemangiomas - current therapeutic strategies. ( Mabeta, P; Pepper, MS, 2011) |
| "Food and Drug Administation for treatment of erythema nodosum in leprosy and is now approved for multiple myeloma as well." | 2.46 | Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders. ( Ladizinski, B; Levis, WR; Sanchez, MR; Shannon, EJ, 2010) |
| "Treatment with thalidomide stopped the progression of the disease in two cases." | 1.91 | Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report. ( Abdollahimajd, F; Diab, R; Kaddah, A; Rakhshan, A; Shahidi Dadras, M, 2023) |
| "Thalidomide treatment finally led to complete remission." | 1.36 | Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination. ( Beylot-Barry, M; Doutre, MS; Pham-Ledard, A; Vergier, B, 2010) |
| "Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies." | 1.34 | A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma. ( Ben M'barek, L; Biet, I; Fardet, L; Kérob, D; Lebbe, C; Mebazaa, A; Morel, P; Thervet, E, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.08) | 18.7374 |
| 1990's | 1 (2.04) | 18.2507 |
| 2000's | 27 (55.10) | 29.6817 |
| 2010's | 18 (36.73) | 24.3611 |
| 2020's | 1 (2.04) | 2.80 |
| Authors | Studies |
|---|---|
| Diab, R | 1 |
| Shahidi Dadras, M | 1 |
| Rakhshan, A | 1 |
| Kaddah, A | 1 |
| Abdollahimajd, F | 1 |
| Bagot, M | 1 |
| Hasan, B | 1 |
| Whittaker, S | 1 |
| Beylot-Barry, M | 2 |
| Knobler, R | 1 |
| Shah, E | 1 |
| Marreaud, S | 1 |
| Morris, S | 1 |
| Dalle, S | 1 |
| Servitje, O | 1 |
| Cowan, R | 1 |
| Väkevä, L | 1 |
| Chaby, G | 1 |
| Jonak, C | 1 |
| Fox, CP | 1 |
| Ritchie, D | 1 |
| Vermeer, MH | 1 |
| Stadler, R | 1 |
| Romero, PLO | 1 |
| Scarisbrick, J | 1 |
| Quaglino, P | 1 |
| Chavarot, N | 1 |
| Lebbe, C | 2 |
| Thervet, E | 2 |
| Bouscary, D | 1 |
| Karras, A | 1 |
| Wang, X | 1 |
| Wu, L | 1 |
| Shi, X | 1 |
| He, X | 1 |
| Li, W | 1 |
| Zhou, H | 1 |
| Ossorio-García, L | 1 |
| Jiménez-Gallo, D | 1 |
| Collantes-Rodríguez, C | 1 |
| Báez-Perea, JM | 1 |
| Linares-Barrios, M | 1 |
| Savini, P | 1 |
| Lanzi, A | 1 |
| Foschi, FG | 1 |
| Marano, G | 1 |
| Stefanini, GF | 1 |
| Boyapati, A | 1 |
| Khan, S | 1 |
| Mar, A | 1 |
| Sheridan, A | 1 |
| Mishchenko, E | 1 |
| Attias, D | 1 |
| Tadmor, T | 1 |
| Desnoyer, A | 1 |
| Dupin, N | 1 |
| Assoumou, L | 1 |
| Carlotti, A | 1 |
| Gaudin, F | 1 |
| Deback, C | 1 |
| Peytavin, G | 1 |
| Marcelin, AG | 1 |
| Boué, F | 2 |
| Balabanian, K | 1 |
| Pourcher, V | 1 |
| Burki, TK | 1 |
| Vestermark, LW | 1 |
| Larsen, S | 1 |
| Lindeløv, B | 1 |
| Bastholt, L | 1 |
| Lee, JH | 1 |
| Cheng, AL | 1 |
| Lin, CW | 1 |
| Kuo, SH | 1 |
| Lutzky, J | 1 |
| Weber, R | 1 |
| Nunez, Y | 1 |
| Gillett, M | 1 |
| Spitler, L | 1 |
| Ott, PA | 1 |
| Chang, JL | 1 |
| Oratz, R | 1 |
| Jones, A | 1 |
| Farrell, K | 1 |
| Muggia, F | 1 |
| Pavlick, AC | 1 |
| Glaspy, J | 2 |
| Atkins, MB | 1 |
| Richards, JM | 1 |
| Agarwala, SS | 1 |
| O'Day, S | 1 |
| Knight, RD | 2 |
| Jungnelius, JU | 2 |
| Bedikian, AY | 1 |
| Eisen, T | 1 |
| Trefzer, U | 1 |
| Hamilton, A | 1 |
| Hersey, P | 1 |
| Millward, M | 1 |
| Clark, JI | 2 |
| Moon, J | 2 |
| Hutchins, LF | 2 |
| Sosman, JA | 1 |
| Kast, WM | 1 |
| Da Silva, DM | 1 |
| Liu, PY | 1 |
| Thompson, JA | 2 |
| Flaherty, LE | 2 |
| Sondak, VK | 2 |
| Pham-Ledard, A | 1 |
| Vergier, B | 1 |
| Doutre, MS | 1 |
| Franklin, BE | 1 |
| Oprea, M | 1 |
| Franklin, SM | 1 |
| Ladizinski, B | 1 |
| Shannon, EJ | 1 |
| Sanchez, MR | 1 |
| Levis, WR | 1 |
| Passeron, T | 1 |
| Martinez, V | 1 |
| Tateo, M | 1 |
| Castilla, MA | 1 |
| Melica, G | 1 |
| Kirstetter, M | 1 |
| Mabeta, P | 1 |
| Pepper, MS | 1 |
| Akasbi, Y | 1 |
| Awada, A | 1 |
| Arifi, S | 1 |
| Mellas, N | 1 |
| El Mesbahi, O | 1 |
| Lindner, DJ | 1 |
| Gachon, J | 1 |
| Grob, JJ | 1 |
| Richard, MA | 1 |
| González-Porras, JR | 1 |
| González, M | 1 |
| García-Sanz, R | 1 |
| San Miguel, JF | 1 |
| Danson, S | 1 |
| Lorigan, P | 1 |
| Arance, A | 1 |
| Clamp, A | 1 |
| Ranson, M | 1 |
| Hodgetts, J | 1 |
| Lomax, L | 1 |
| Ashcroft, L | 1 |
| Thatcher, N | 1 |
| Middleton, MR | 1 |
| Bartlett, JB | 1 |
| Michael, A | 1 |
| Clarke, IA | 1 |
| Dredge, K | 1 |
| Nicholson, S | 1 |
| Kristeleit, H | 1 |
| Polychronis, A | 1 |
| Pandha, H | 1 |
| Muller, GW | 1 |
| Stirling, DI | 1 |
| Zeldis, J | 1 |
| Dalgleish, AG | 1 |
| Pawlak, WZ | 1 |
| Legha, SS | 1 |
| Reiriz, AB | 1 |
| Richter, MF | 1 |
| Fernandes, S | 1 |
| Cancela, AI | 1 |
| Costa, TD | 1 |
| Di Leone, LP | 1 |
| Schwartsmann, G | 1 |
| Hwu, WJ | 2 |
| Lis, E | 1 |
| Menell, JH | 1 |
| Panageas, KS | 1 |
| Lamb, LA | 1 |
| Merrell, J | 1 |
| Williams, LJ | 1 |
| Krown, SE | 2 |
| Chapman, PB | 1 |
| Livingston, PO | 1 |
| Wolchok, JD | 1 |
| Houghton, AN | 2 |
| Brightman, L | 1 |
| Demierre, MF | 1 |
| Heere-Ress, E | 1 |
| Boehm, J | 1 |
| Thallinger, C | 1 |
| Hoeller, C | 1 |
| Wacheck, V | 1 |
| Birner, P | 1 |
| Wolff, K | 1 |
| Pehamberger, H | 1 |
| Jansen, B | 1 |
| Laber, DA | 1 |
| Okeke, RI | 1 |
| Arce-Lara, C | 1 |
| Taft, BS | 1 |
| Schonard, CL | 1 |
| McMasters, KM | 1 |
| Kloecker, GH | 1 |
| Miller, DM | 1 |
| Niedzwiecki, D | 1 |
| Hodgson, L | 1 |
| Haluska, FG | 1 |
| Ramadan, KM | 1 |
| McKenna, KE | 1 |
| Morris, TC | 1 |
| Pauzner, R | 1 |
| Mayan, H | 1 |
| Waizman, A | 1 |
| Rozenman, J | 1 |
| Farfel, Z | 1 |
| Solti, M | 1 |
| Berd, D | 1 |
| Mastrangelo, MJ | 1 |
| Sato, T | 1 |
| Laffitte, E | 1 |
| Ben M'barek, L | 1 |
| Fardet, L | 1 |
| Mebazaa, A | 1 |
| Biet, I | 1 |
| Kérob, D | 1 |
| Morel, P | 1 |
| Lange, MK | 1 |
| Carlesimo, M | 1 |
| Giustini, S | 1 |
| Rossi, A | 1 |
| Bonaccorsi, P | 1 |
| Calvieri, S | 1 |
| Bladé, J | 1 |
| Perales, M | 1 |
| Rosiñol, L | 1 |
| Tuset, M | 1 |
| Montoto, S | 1 |
| Esteve, J | 1 |
| Cobo, F | 1 |
| Villela, L | 1 |
| Rafel, M | 1 |
| Nomdedeu, B | 1 |
| Montserrat, E | 1 |
| Kudva, GC | 1 |
| Collins, BT | 1 |
| Dunphy, FR | 1 |
| Avigdor, A | 1 |
| Raanani, P | 1 |
| Levi, I | 1 |
| Hardan, I | 1 |
| Ben-Bassat, I | 1 |
| Nathan, PD | 1 |
| Eisen, TG | 1 |
| Roe, FJ | 1 |
| Walters, MA | 1 |
| Miura, M | 1 |
| Southam, CM | 1 |
| Wuest, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Lenalidomide Maintenance Therapy in Stage IIIB/IV Non-small Cell Lung Cancer After First-line Chemotherapy[NCT02018523] | Phase 1 | 7 participants (Actual) | Interventional | 2014-06-30 | Terminated (stopped due to Study did not enroll enough subjects to make a statistically sound conclusion.) | ||
| Multicenter, Randomized, Double-blind, Placebo-controlled Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma Whose Disease Has Progressed on Treatment With DTIC, IL-2, or IFN Based Therapy[NCT00057616] | Phase 3 | 274 participants | Interventional | 2002-10-01 | Completed | ||
| A Phase II Trial of Combination Thalidomide Plus Temozolomide in Patients With Metastatic Malignant Melanoma[NCT00104988] | Phase 2 | 64 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Evaluation of Interferon Alpha-2b and Thalidomide in Patients With Disseminated Malignant Melanoma, Phase II[NCT00026520] | Phase 2 | 0 participants | Interventional | 2001-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for thalidomide and Skin Neoplasms
| Article | Year |
|---|---|
Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Topics: Behcet Syndrome; Dermatitis; Erythema Nodosum; Humans; Immunomodulation; Lupus Erythematosus, Cutane | 2010 |
[What's new in dermatological research?].
Topics: Biomedical Research; Dermatitis, Atopic; Dermatology; Herpesviridae Infections; HIV Infections; Huma | 2010 |
Hemangiomas - current therapeutic strategies.
Topics: Angiogenesis Inhibitors; Bleomycin; Child; Cyclophosphamide; Hemangioma; Humans; Interferons; Neovas | 2011 |
Non-HIV Kaposi's sarcoma: a review and therapeutic perspectives.
Topics: Age Factors; Antineoplastic Agents; Antiviral Agents; Female; Herpesvirus 8, Human; Humans; Male; Mo | 2012 |
Interferons as antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Syne | 2002 |
The biological treatment of renal-cell carcinoma and melanoma.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Hematopoietic Stem Cell Transplantation; Hu | 2002 |
17 trials available for thalidomide and Skin Neoplasms
| Article | Year |
|---|---|
A phase III study of lenalidomide maintenance after debulking therapy in patients with advanced cutaneous T-cell lymphoma - EORTC 21081 (NCT01098656): results and lessons learned for future trial designs.
Topics: Aged; Angiogenesis Inhibitors; Cytoreduction Surgical Procedures; Disease Progression; Disease-Free | 2017 |
Expression pattern of the CXCL12/CXCR4-CXCR7 trio in Kaposi sarcoma skin lesions.
Topics: Adult; Angiogenesis Inhibitors; Antigens, Viral; Biomarkers, Tumor; Case-Control Studies; Chemokine | 2016 |
A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Brain Neoplasms; Disease Progression; Disease-Free Survival; F | 2008 |
A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
Topics: Adjuvants, Immunologic; Adult; Aged; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Human | 2009 |
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Dose-Response Relationship | 2009 |
Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Administration Schedule; Female; Humans; Lenalidomi | 2009 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma.
Topics: Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Resistance, Neoplasm; Female; | 2010 |
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; | 2010 |
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2003 |
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cytokines; Female; Fibroblast G | 2004 |
Phase II study of thalidomide in patients with metastatic melanoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Disease Progression; Female; Humans; Lung Neoplasms; Male; Max | 2004 |
Phase II study of thalidomide in patients with metastatic malignant melanoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Drug Administration Schedule; Female; Fi | 2004 |
Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2005 |
A phase II study of extended dose temozolomide and thalidomide in previously treated patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Disease Progression; Dose- | 2006 |
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dac | 2006 |
A pilot study of low-dose thalidomide and interferon alpha-2b in patients with metastatic melanoma who failed prior treatment.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progressi | 2007 |
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Interferon alpha-2; Interferon-alpha; Male; Melanoma | 2007 |
26 other studies available for thalidomide and Skin Neoplasms
| Article | Year |
|---|---|
Progressive mucinous histiocytosis treated successfully with thalidomide: a rare case report.
Topics: Adult; Female; Histiocytosis; Humans; Skin Diseases; Skin Neoplasms; Thalidomide | 2023 |
Bortezomib Does Not Prevent the Occurrence of Kaposi's Sarcoma in Patients with Haematological Malignancies: Two Case Reports.
Topics: Aged; Amyloidosis; Antineoplastic Agents; Bortezomib; Female; Humans; Immunologic Factors; Lenalidom | 2017 |
Extramammary Paget's disease of the oral mucosa and perioral skin.
Topics: Angiogenesis Inhibitors; Diagnosis, Differential; Female; Humans; Middle Aged; Mouth Neoplasms; Page | 2017 |
Treatment of inflammatory linear verrucous epidermal nevus pruritus with thalidomide.
Topics: Adult; Antipruritics; Humans; Male; Nevus, Sebaceous of Jadassohn; Pruritus; Skin Neoplasms; Thalido | 2018 |
Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type.
Topics: Aged, 80 and over; Angiogenesis Inhibitors; Female; Humans; Leg; Lenalidomide; Lymphoma, Large B-Cel | 2014 |
Reactive angioendotheliomatosis associated with cyroglobulinemia in a marathon runner.
Topics: Aged; Angiogenesis Inhibitors; Cryoglobulinemia; Hemangioendothelioma; Humans; Lenalidomide; Male; R | 2013 |
Response of cutaneous lesion of mantle cell lymphoma to lenalidomide.
Topics: Aged, 80 and over; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Male; Skin; Ski | 2014 |
Pomalidomide for symptomatic Kaposi's sarcoma.
Topics: Antineoplastic Agents, Immunological; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II a | 2016 |
Multifocal primary cutaneous CD30+ anaplastic large cell lymphoma responsive to thalidomide: the molecular mechanism and the clinical application.
Topics: Antineoplastic Agents; Female; Humans; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Male; Midd | 2009 |
Disseminated cutaneous lymphoid hyperplasia of 12 years' duration triggered by vaccination.
Topics: Adolescent; B-Lymphocytes; CD3 Complex; Cyclins; DNA-Binding Proteins; Female; Hepatitis B Vaccines; | 2010 |
Chest nodule in a patient with multiple myeloma.
Topics: Aged; Biopsy; Humans; Immunosuppressive Agents; Male; Multiple Myeloma; Skin Neoplasms; Thalidomide; | 2010 |
Lenalidomide in treating AIDS-related Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; HIV-1; Humans; Lenalidomide; Sarcoma, Kaposi; Skin Neoplasms; Th | 2011 |
[Thrombotic accidents induced by thalidomide: two cases].
Topics: Adult; Aged; Female; Humans; Immunosuppressive Agents; Lupus Vulgaris; Male; Melanoma; Multiple Myel | 2002 |
Thalidomide in combination with cyclophosphamide and dexamethasone (thacydex) is effective in soft-tissue plasmacytomas.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clavicle; Cyclophosphamide; Dexamethasone; Dru | 2002 |
Thalidomide in mycosis fungoides.
Topics: Adult; Female; Humans; Immunosuppressive Agents; Mycosis Fungoides; Skin Neoplasms; Thalidomide | 2005 |
Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Alkylating; Dacarbazine; Drug Therapy, Comb | 2005 |
Clinical response of cutaneous squamous-cell carcinoma to bortezomib given for myeloma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bor | 2006 |
Successful thalidomide treatment of persistent chylous pleural effusion in disseminated lymphangiomatosis [corrected].
Topics: Angiogenesis Inhibitors; Bone Neoplasms; Chylothorax; Female; Humans; Lymphangiomyoma; Middle Aged; | 2007 |
Thalidomide in Kaposi sarcoma: promising or disappointing?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Lenalidomide; Sarcoma, Kaposi; Skin Neoplasm | 2007 |
A retrospective analysis of thalidomide therapy in non-HIV-related Kaposi's sarcoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Female; HIV Infectio | 2007 |
Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
Topics: Aged; Female; Humans; Middle Aged; Sarcoidosis; Sarcoidosis, Pulmonary; Sarcoma, Kaposi; Skin Diseas | 1995 |
Thalidomide in multiple myeloma: lack of response of soft-tissue plasmacytomas.
Topics: Aged; Bone Marrow Cells; Connectin; Drug Administration Schedule; Female; Humans; Immunosuppressive | 2001 |
Thalidomide for malignant melanoma.
Topics: Humans; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Skin Neoplasms; Thalidomide | 2001 |
Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.
Topics: Adult; Bone Marrow; Bone Marrow Neoplasms; Brain Neoplasms; Disease Progression; Humans; Male; Middl | 2001 |
Sensitivity of newborn mice to carcinogenic agents.
Topics: Adenocarcinoma; Adenoma; Animals; Animals, Newborn; Benz(a)Anthracenes; Carcinogens; Carcinoma, Hepa | 1968 |
Potentiating effect of thalidomide on methylcholanthrene oncogenesis in mice.
Topics: Animals; Antibody Formation; Cell Count; Cell Transformation, Neoplastic; Drug Synergism; Female; He | 1970 |